Athena Athena

X
[{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AELIX Has Presented Positive Results from the Clinical Study AELIX-002 at the 2021 Conference on Retroviruses and Opportunistic Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Aelix Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            HTI-based vaccines as a component of combination cure regimens are being evaluated in the ongoing AELIX-003 clinical trial testing HTI in combination with Gilead’s investigational TLR7 agonist vesatolimod, in people living with HIV on ART.

            Lead Product(s): Vesatolimod

            Therapeutic Area: Infections and Infectious Diseases Product Name: GS-9620

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY